Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth, while full-year revenue reached $727 million, a 10% increase over 2024 [8][23] - Adjusted gross profit improved by $5.8 million, or 7% year-over-year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million, slightly down from Q3 [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies and growth in test volumes [8][20] - NGS revenue grew by 23% year-over-year, accounting for about one-third of total clinical revenue [21] - Non-clinical revenue declined by over 25% in Q4 and 24% for the full year, aligning with revised expectations [20][23] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% market share [10] - Approximately 40% of active pathologists and oncologists ordered five or more tests from the company during the year, indicating significant market penetration [11] Company Strategy and Development Direction - The company aims to drive strategic, profitable growth through continued expansion of NGS revenues and market penetration for the PanTracer family and RaDaR ST [29] - The focus is on enhancing customer workflows and productivity through investments in technology and automation [29] - The company plans to expand its sales force to support the launch of RaDaR ST and penetrate the head and neck market [14][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2026, expecting revenues between $793 million and $801 million, with a focus on RaDaR ST and PanTracer Liquid contributions [25][27] - The company anticipates modest erosion in the pharma business for 2026, with a return to growth expected in 2027 [70][74] Other Important Information - The company is preparing for a full clinical launch of the RaDaR ST MRD assay, with expectations for revenue growth to accelerate in 2027 and beyond [14][27] - The integration of a common LIMS system is expected to enhance operational efficiencies and customer experience, with more pronounced benefits anticipated in 2027 and 2028 [59][63] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep expansion? - Management confirmed the full launch of RaDaR ST is planned for the end of the month, focusing on head and neck and breast cancer indications, with an initial sales force expansion targeting ENTs [34][38] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts is expected to lead to higher AUP growth, with a focus on therapy selection and MRD driving overall revenue growth [45][46] Question: What are the expectations for the pharma business in 2026? - Management anticipates modest erosion in the pharma business for 2026, with a return to growth expected in 2027, driven by RaDaR ST [70][74] Question: How is the sales force performing after recent expansions? - The sales force is expected to contribute positively to growth, with oncology sales specialists focusing on therapy selection and supporting the RaDaR ST launch [90]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth, while full-year revenue reached $727 million, a 10% increase over 2024 [8][23] - Adjusted gross profit improved by $5.8 million, or 7% year-over-year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million, slightly down from Q3 [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies and a 23% growth in NGS revenue [8][20] - Non-clinical revenue declined by over 25% in Q4, consistent with expectations [20] - Average revenue per clinical test (AUP) increased by 5% year-over-year, with a sequential increase of 3% from Q3 [21] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% share across diagnostics and therapy selections [10] - Approximately 40% of active pathologists and oncologists ordered five or more tests from the company during the year, indicating significant market penetration [11] Company Strategy and Development Direction - The company aims to drive growth through strategic investments in NGS and MRD initiatives, with a focus on expanding its oncology sales force [29] - The launch of the RaDaR ST MRD assay is set for the end of the month, with plans to expand the sales force to penetrate the head and neck market [13][14] - The company is also focusing on enhancing operational efficiencies through technology and automation investments [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth in 2026, projecting revenues between $793 million and $801 million, with a focus on high-margin modalities [25][27] - The company anticipates modest revenue contributions from RaDaR ST in 2026, with expectations for accelerated growth in 2027 and beyond [14][25] - Management acknowledged potential impacts from extreme weather on Q1 volumes but remains optimistic about meeting full-year guidance [26] Other Important Information - The company has submitted additional solid tumor cancer indications for MolDX approval, which could double the market opportunity for RaDaR ST testing [14] - The PanTracer portfolio is expanding, with strong growth in PanTracer Tissue tests and the recent launch of PanTracer Pro [17] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep expansion? - Management confirmed the full launch of RaDaR ST at the end of the month, focusing on head and neck and breast cancer indications, with an initial expansion of sales reps dedicated to these areas [34][38] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts would lead to higher AUP growth, with expectations for AUPs in the upper single-digit range and volume growth in the lower- to mid-single-digit range [45][46] Question: What are the expectations for pharma ordering in 2026? - Management anticipates modest erosion in the pharma business for 2026, with RaDaR ST expected to be a key growth driver [70][74] Question: Can you discuss the LIMS rollout and its impact on earnings? - The LIMS integration is ongoing, with benefits expected to materialize in 2027 and 2028, while operational efficiencies will begin to show in 2026 [60][62]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth [6] - Full year total revenue reached $727 million, a 10% increase over 2024 [24] - Adjusted gross profit improved by $5.8 million, or 7% over the prior year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies [6] - NGS revenue grew by 23% year-over-year, accounting for about one-third of total clinical revenue [21] - Non-clinical revenue declined by over 25% in Q4, with a full year decline of 24% [20][24] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% market share [9] - Approximately 40% of active pathologists and oncologists ordered five or more tests from NeoGenomics during the year [10] Company Strategy and Development Direction - The company aims to drive growth through the expansion of NGS revenues and market penetration for the PanTracer family and RaDaR ST [29] - A focus on strategic, profitable growth is emphasized, with investments in sales and marketing and R&D for new product initiatives [28] - The company is preparing for a full clinical launch of the RaDaR ST MRD assay, which is expected to enhance market opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2026, expecting revenues between $793 million and $801 million [26] - The company anticipates modest revenue contributions from RaDaR ST in 2026, with growth expected to accelerate in 2027 and beyond [13] - Management acknowledged potential impacts from extreme weather on Q1 volumes but remains optimistic about overall growth [27] Other Important Information - The company has launched five NGS products since March 2023, contributing significantly to revenue growth [18] - The acquisition of PathLine is expected to provide operational efficiencies and synergies that will be accretive to profitability [10] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep focus? - Management confirmed the full launch of RaDaR ST is planned for the end of the month, focusing on head and neck and subsets of breast cancer [34] - The initial sales force expansion will target the head and neck market, with plans to add more reps for future indications [36] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts will lead to higher AUPs and better margins, with expectations for AUP growth in the upper single-digit range [44] Question: Can you clarify guidance for the core clinical business? - Management expects the core clinical business to grow at about 10%, factoring in the full year of PathLine and the impact of exiting low-value contracts [52] Question: What is the framework for LIMS integration this year? - The company is migrating to a common LIMS system, with benefits expected to materialize in 2027, while optimizing workflows for efficiency [57] Question: What is the potential for continued ASP growth? - Continued growth in AUP is anticipated, driven by the shift into NGS and managed care pricing increases [84]

Core Insights - NeoGenomics, Inc. has launched a new pan-solid tumor assay called PanTracer Pro, aimed at assisting clinicians in navigating complex molecular testing workflows for patients with advanced-stage solid tumors [1][2] - The company has reported a significant increase in its stock price, with shares rising 82.4% over the past six months, outperforming the industry and the S&P 500 Index [3] - NeoGenomics' revenues have shown a consistent upward trend, with a 36.6% increase from 2021 to 2024, and preliminary results for 2025 indicate a year-over-year sales growth of 10% to $727 million [4][5] Product Development - The PanTracer Pro assay is designed to streamline testing processes in precision oncology, combining DNA and RNA sequencing of over 500 cancer-related genes with tumor-specific ancillary testing [6][10] - This new assay aims to reduce diagnostic complexity and turnaround time, facilitating timely treatment decisions for cancer patients [2][10] - In cases where tissue samples are insufficient, clinicians can transition to the PanTracer LBx liquid biopsy assay without restarting the diagnostic process, thus avoiding delays in patient care [11] Financial Performance - NeoGenomics reported Q4 sales of approximately $190 million, reflecting an 11% increase year over year, and anticipates continued double-digit growth in 2026 [8][12] - The company expects ongoing top-line growth driven by the increasing adoption of precision oncology and its comprehensive suite of oncology tests [5][8] Market Position - The launch of PanTracer Pro is expected to enhance NeoGenomics' competitive position in the precision oncology market by addressing the challenges of fragmented testing workflows and supporting personalized treatment planning [9][10] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook compared to other stocks in the medical sector [13]

NeoGenomics (Nasdaq: NEO) JP Morgan Healthcare Conference Investor Presentation January 2026 Mission We save lives by improving patient care. Vision We are becoming the world's leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services. Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein ar ...